Skip to content
Inciteful Med

Biology & Pathology: Auditing Your Pathology Report

Last updated:

A pituitary pathology report reveals the tumor's cellular lineage and growth rate to guide your care. Key details to check include the updated classification name (PitNET), transcription factors like SF-1 or T-PIT, and the Ki-67 index, which shows how fast the tumor is growing.

Key Takeaways

  • • The World Health Organization renamed pituitary adenomas to Pituitary Neuroendocrine Tumors (PitNETs) in 2022 to better reflect their biological potential.
  • • Testing for transcription factors like SF-1, T-PIT, and PIT-1 identifies the tumor's cellular lineage and helps predict its future behavior.
  • • Growth markers, including the Ki-67 index and mitotic count, reveal how fast the tumor cells are actively dividing.
  • • A true null cell tumor is a rare diagnosis that requires negative test results for all hormones and all major transcription factors.
  • • Patients should review their pathology reports to ensure critical data points like the Ki-67 index, transcription factors, and invasion status are clearly listed.

When your tumor is removed, a doctor called a pathologist examines the tissue under a microscope. Their report is the “gold standard” for understanding your diagnosis. Recently, the way these tumors are classified changed significantly to help doctors better predict how they will behave [1][2].

From Adenoma to PitNET

In 2022, the World Health Organization (WHO) officially changed the name of these growths from “pituitary adenoma” to Pituitary Neuroendocrine Tumor (PitNET) [3][4].

This change emphasizes that these tumors are part of a family of “neuroendocrine” tumors that can appear elsewhere in the body [1]. While most remain slow-growing and do not spread, the WHO updated their classification code to reflect that they have the potential to be more persistent, moving them from a “0” (benign) to a “3” (primary malignant) behavior code in certain databases [2]. This doesn’t mean your tumor has become “cancer” overnight; it means the medical community is taking their potential for growth more seriously [5].

The “Genetic Blueprint”: Transcription Factors and Why They Matter

A modern pathology report no longer just looks at what hormones a tumor secretes; it looks at the tumor’s lineage—essentially its family tree [3][6]. This is determined by testing for transcription factors, which are “master switches” in a cell’s DNA [7]. Knowing this lineage helps doctors predict how aggressively the tumor might grow and how closely it needs to be monitored.

  • SF-1 (Steroidogenic Factor 1): Indicates a gonadotroph lineage. These are the most common type of non-functioning tumors. They generally grow slowly and are less likely to rapidly recur [8][9].
  • T-PIT: Indicates a corticotroph lineage. Even if the tumor doesn’t produce hormones (a “silent” tumor), T-PIT positive tumors can sometimes be more aggressive and larger, which might prompt your care team to recommend more frequent MRIs [8][10].
  • PIT-1: Indicates a lineage that usually produces growth hormone or prolactin. If found in a non-functioning tumor, it is often called an “immature PIT-1” tumor, which also may require careful surveillance [11][12].

Measuring Growth: Ki-67 and Mitosis

Pathologists use two main “speedometers” to see how fast the tumor cells were dividing. This answers the vital patient question: “Is my tumor a fast grower?”

  1. Ki-67 Index: This is a percentage of cells that are actively growing. In most NFPAs, this is 2% or less [13]. A Ki-67 higher than 3% may suggest a higher risk of the tumor growing back later, leading to more frequent follow-up scans or the need for radiation [13][14].
  2. Mitotic Count: This is a physical count of how many cells were caught in the middle of dividing (mitosis) when the sample was taken [15].

What is a “Null Cell” Tumor?

In the past, many tumors were called “null cell.” Today, a true null cell adenoma is a very specific and rare diagnosis. It means the tumor tested negative for all hormones AND negative for all three master transcription factors (PIT-1, T-PIT, and SF-1) [16][17]. If your report says “null cell,” you should ensure all three transcription factors were actually tested [18].

Pathology Completeness Checklist

To ensure your care team has the best information, check your report for these data points:

  • [ ] Diagnosis Name: Does it use “Pituitary Neuroendocrine Tumor” (PitNET)? [2]
  • [ ] Transcription Factors: Are PIT-1, T-PIT, and SF-1 results listed? [19]
  • [ ] Hormone Stains: Did they test for ACTH, GH, PRL, TSH, LH, and FSH? [20]
  • [ ] Ki-67 Index: Is there a percentage (e.g., 2%) listed? [21]
  • [ ] Mitotic Count: Is a count provided (e.g., <1 per 10 HPF)? [15]
  • [ ] Invasion: Does the report mention if the tumor was seen invading nearby bone or “dura” (the brain’s lining)? [22]

If any of these are missing, it is worth asking your doctor if “supplemental immunohistochemistry” is needed to complete the picture.

Frequently Asked Questions

What is a PitNET and how is it different from a pituitary adenoma?
PitNET stands for Pituitary Neuroendocrine Tumor. In 2022, the World Health Organization updated the name from 'pituitary adenoma' to reflect that these tumors belong to a larger family of neuroendocrine growths.
What does the Ki-67 index mean on my pathology report?
The Ki-67 index measures the percentage of tumor cells that are actively dividing and growing. Most non-functioning pituitary tumors have an index of 2% or less, while a higher percentage suggests the tumor may grow back faster and require closer monitoring.
Why do doctors test for transcription factors in pituitary tumors?
Transcription factors like SF-1, T-PIT, and PIT-1 act as master switches in a cell's DNA that reveal the tumor's lineage. Identifying this lineage helps your doctors predict how the tumor might behave and how often you need follow-up MRI scans.
What does it mean if my report says I have a null cell tumor?
A true null cell tumor is a rare diagnosis indicating the tumor tested negative for all hormones and negative for all three major transcription factors. If your report says null cell, you should verify with your doctor that all three transcription factors were actually tested.
Does the new 'primary malignant' behavior code mean I have brain cancer?
No, this behavior code change does not mean your tumor has suddenly become cancer. It simply reflects that the medical community recognizes these tumors have the potential to grow persistently and require careful, long-term monitoring.

Questions for Your Doctor

  • • My report mentions [Lineage X] based on my transcription factor results—what does this specific lineage tell us about how my tumor might behave in the future?
  • • Is my Ki-67 index of [Percentage]% considered high for this type of PitNET, and should that change how often we do follow-up scans?
  • • If my tumor is a 'null cell' tumor, were all three transcription factors (PIT-1, T-PIT, and SF-1) tested to confirm this?
  • • Does the pathology report indicate any 'micro-invasion' that wasn't visible on my initial MRI?
  • • Now that the WHO calls these 'PitNETs' and uses a behavior code of '3' (primary malignant), does that mean we should treat this more aggressively than if it were called a 'benign adenoma'?

Questions for You

  • • Does my pathology report use the term 'Pituitary Neuroendocrine Tumor' (PitNET) or 'Adenoma'?
  • • Can I find the 'Ki-67' percentage on my report? Is it a number like 1%, 2%, or higher?
  • • Looking at the 'Immunohistochemistry' section, which markers (like SF-1 or PIT-1) have a '+' or 'positive' sign next to them?
  • • Did I get a copy of the 'gross description' and 'microscopic description' from the pathologist, or just the final summary?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [WHO Histological Classification of Pituitary Tumors].

    Nishioka H

    No shinkei geka. Neurological surgery 2023; (51(4)):642-653 doi:10.11477/mf.1436204797.

    PMID: 37491061
  2. 2

    Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.

    Tsukamoto T, Miki Y

    Japanese journal of radiology 2023; (41(8)):789-806 doi:10.1007/s11604-023-01400-7.

    PMID: 36826759
  3. 3

    [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].

    Kurosaki M

    No shinkei geka. Neurological surgery 2023; (51(5)):910-916 doi:10.11477/mf.1436204833.

    PMID: 37743343
  4. 4

    Progress in the pathogenesis and treatment of pituitary neuroendocrine tumors (PitNETs): From molecular mechanisms to emerging therapies.

    Wu N, Wu N, Wang N, Zhu Y

    Molecular and cellular probes 2025; (83()):102039 doi:10.1016/j.mcp.2025.102039.

    PMID: 40581303
  5. 5

    Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients.

    Veleno M, Giampietro A, Raia S, et al.

    Minerva endocrinology 2024; (49(3)):269-282 doi:10.23736/S2724-6507.24.04126-5.

    PMID: 38963295
  6. 6

    A review of multiomics platforms in pituitary adenoma pathogenesis.

    Mouchtouris N, Smit RD, Piper K, et al.

    Frontiers in bioscience (Landmark edition) 2022; (27(3)):77 doi:10.31083/j.fbl2703077.

    PMID: 35345309
  7. 7

    Recommendations on the pathological report of pituitary tumors. A consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology.

    Picó A, Aranda-López I, Sesmilo G, et al.

    Endocrinologia, diabetes y nutricion 2021; (68(3)):196-207 doi:10.1016/j.endien.2020.10.007.

    PMID: 34167699
  8. 8

    Multiple microcysts and clivus invasion diagnose T-box pituitary transcription factor 19 lineage adenomas in non-functioning pituitary adenomas.

    Zhao X, Wang X, Wang S, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2025; (66(4)):441-449 doi:10.1177/02841851251313555.

    PMID: 39865878
  9. 9

    Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors.

    Taniguchi-Ponciano K, Andonegui-Elguera S, Peña-Martínez E, et al.

    Scientific reports 2020; (10(1)):19373 doi:10.1038/s41598-020-76555-8.

    PMID: 33168897
  10. 10

    An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

    Jiang S, Chen X, Wu Y, et al.

    Cancers 2021; (13(23)) doi:10.3390/cancers13236134.

    PMID: 34885244
  11. 11

    GH-Secreting Adenoma or Tumor? Issues in Pituitary Neoplasms Nomenclature, Classification, and Characterization.

    Guaraldi F, Di Sciascio L, Shwaish TZT, et al.

    Frontiers of hormone research 2024; (55()):119-132 doi:10.1159/000539946.

    PMID: 39586264
  12. 12

    Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.

    Mihajlović M, Pekić S, Doknić M, et al.

    International journal of surgical pathology 2024; (32(3)):470-477 doi:10.1177/10668969231183712.

    PMID: 37438981
  13. 13

    Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

    Ogawa Y, Jokura H, Niizuma K, Tominaga T

    Journal of neuro-oncology 2018; (137(3)):543-549 doi:10.1007/s11060-017-2740-1.

    PMID: 29318507
  14. 14

    Aggressive Pituitary Adenoma Not Fulfilling the New High-Risk Criteria with Progression after 18-Year Stable Clinical Course: Case Report.

    Kawaguchi T, Ogawa Y, Watanabe M, Tominaga T

    Journal of neurological surgery. Part A, Central European neurosurgery 2022; (83(4)):391-395 doi:10.1055/s-0040-1722195.

    PMID: 33618408
  15. 15

    Ki-67 labeling index in glioblastoma; does it really matter?

    Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA

    Hematology/oncology and stem cell therapy 2019; (12(2)):82-88 doi:10.1016/j.hemonc.2018.11.001.

    PMID: 30552865
  16. 16

    Overview of the 2017 WHO Classification of Pituitary Tumors.

    Mete O, Lopes MB

    Endocrine pathology 2017; (28(3)):228-243 doi:10.1007/s12022-017-9498-z.

    PMID: 28766057
  17. 17

    Neuropathology of Pituitary Adenomas and Sellar Lesions.

    Kobalka PJ, Huntoon K, Becker AP

    Neurosurgery 2021; (88(5)):900-918 doi:10.1093/neuros/nyaa548.

    PMID: 33476394
  18. 18

    The Role of T-box Transcription Factor in a Pituitary Adenoma Diagnostic Algorithm.

    McDonald WC, McDonald KN, Helmer JA, et al.

    Archives of pathology & laboratory medicine 2021; (145(5)):592-598 doi:10.5858/arpa.2020-0091-OA.

    PMID: 32991684
  19. 19

    Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?

    Lee CH

    Brain tumor research and treatment 2023; (11(3)):173-176 doi:10.14791/btrt.2023.0015.

    PMID: 37550816
  20. 20

    Overview of the 2022 WHO Classification of Pituitary Tumors.

    Asa SL, Mete O, Perry A, Osamura RY

    Endocrine pathology 2022; (33(1)):6-26 doi:10.1007/s12022-022-09703-7.

    PMID: 35291028
  21. 21

    [Histological Classification and Diagnosis of Sellar/Parasellar Tumors].

    Nishioka H

    No shinkei geka. Neurological surgery 2023; (51(5)):789-798 doi:10.11477/mf.1436204820.

    PMID: 37743330
  22. 22

    Newer Concepts in the Classification of Pituitary Adenomas.

    Sathyakumar R, Chacko G

    Neurology India 2020; (68(Supplement)):S7-S12 doi:10.4103/0028-3886.287667.

    PMID: 32611886

This page explains pituitary tumor pathology terminology for educational purposes only. Always consult your pathologist, endocrinologist, or neurosurgeon to interpret your specific report and diagnosis.

Stay up to date

Get notified when new research about Non-functioning pituitary adenoma is published.

No spam. Unsubscribe anytime.